Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 329

1.

Antibodies to the conserved region of the M protein and a streptococcal superantigen cooperatively resolve toxic shock-like syndrome in HLA-humanized mice.

Pandey M, Calcutt A, Ozberk V, Chen Z, Croxen M, Powell J, Langshaw E, Mills JL, Jen FE, McCluskey J, Robson J, Tyrrell GJ, Good MF.

Sci Adv. 2019 Sep 4;5(9):eaax3013. doi: 10.1126/sciadv.aax3013. eCollection 2019 Sep.

PMID:
31517054
2.

Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study.

Osowicki J, Azzopardi KI, Baker C, Waddington CS, Pandey M, Schuster T, Grobler A, Cheng AC, Pollard AJ, McCarthy JS, Good MF, Walker MJ, Dale JB, Batzloff MR, Carapetis JR, Smeesters PR, Steer AC.

Vaccine. 2019 Jun 6;37(26):3485-3494. doi: 10.1016/j.vaccine.2019.03.059. Epub 2019 May 14.

PMID:
31101422
3.

Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines.

Ssemaganda A, Giddam AK, Zaman M, Skwarczynski M, Toth I, Stanisic DI, Good MF.

Front Immunol. 2019 Feb 1;10:135. doi: 10.3389/fimmu.2019.00135. eCollection 2019. Review.

4.

Challenges and strategies for developing efficacious and long-lasting malaria vaccines.

Beeson JG, Kurtovic L, Dobaño C, Opi DH, Chan JA, Feng G, Good MF, Reiling L, Boyle MJ.

Sci Transl Med. 2019 Jan 9;11(474). pii: eaau1458. doi: 10.1126/scitranslmed.aau1458. Review.

PMID:
30626712
5.

Cross-Species Immune Recognition Between Plasmodium vivax Duffy Binding Protein Antibodies and the Plasmodium falciparum Surface Antigen VAR2CSA.

Gnidehou S, Mitran CJ, Arango E, Banman S, Mena A, Medawar E, Lima BAS, Doritchamou J, Rajwani J, Jin A, Gavina K, Ntumngia F, Duffy P, Narum D, Ndam NT, Nielsen MA, Salanti A, Kano FS, Carvalho LH, Adams JH, Maestre A, Good MF, Yanow SK.

J Infect Dis. 2019 Jan 1;219(1):110-120. doi: 10.1093/infdis/jiy467.

PMID:
30534974
6.

Investigation of group A Streptococcus immune responses in an endemic setting, with a particular focus on J8.

Campbell PT, Frost H, Smeesters PR, Kado J, Good MF, Batzloff M, Geard N, McVernon J, Steer A.

Vaccine. 2018 Nov 29;36(50):7618-7624. doi: 10.1016/j.vaccine.2018.10.091. Epub 2018 Nov 3.

PMID:
30401621
7.

Controlled Infection Immunization Using Delayed Death Drug Treatment Elicits Protective Immune Responses to Blood-Stage Malaria Parasites.

Low LM, Ssemaganda A, Liu XQ, Ho MF, Ozberk V, Fink J, Sundac L, Alcorn K, Morrison A, O'Callaghan K, Gerrard J, Stanisic DI, Good MF.

Infect Immun. 2018 Dec 19;87(1). pii: e00587-18. doi: 10.1128/IAI.00587-18. Print 2019 Jan.

8.

Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naïve volunteers: a pilot study.

Stanisic DI, Fink J, Mayer J, Coghill S, Gore L, Liu XQ, El-Deeb I, Rodriguez IB, Powell J, Willemsen NM, De SL, Ho MF, Hoffman SL, Gerrard J, Good MF.

BMC Med. 2018 Oct 8;16(1):184. doi: 10.1186/s12916-018-1173-9.

9.

Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus.

Nevagi RJ, Khalil ZG, Hussein WM, Powell J, Batzloff MR, Capon RJ, Good MF, Skwarczynski M, Toth I.

Acta Biomater. 2018 Oct 15;80:278-287. doi: 10.1016/j.actbio.2018.09.037. Epub 2018 Sep 25.

PMID:
30266637
10.

Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial.

Sekuloski S, Batzloff MR, Griffin P, Parsonage W, Elliott S, Hartas J, O'Rourke P, Marquart L, Pandey M, Rubin FA, Carapetis J, McCarthy J, Good MF.

PLoS One. 2018 Jul 2;13(7):e0198658. doi: 10.1371/journal.pone.0198658. eCollection 2018.

11.

Contribution of cryptic epitopes in designing a group A streptococcal vaccine.

Ozberk V, Pandey M, Good MF.

Hum Vaccin Immunother. 2018;14(8):2034-2052. doi: 10.1080/21645515.2018.1462427. Epub 2018 Jun 14.

12.

Skin infection boosts memory B-cells specific for a cryptic vaccine epitope of group A streptococcus and broadens the immune response to enhance vaccine efficacy.

Pandey M, Ozberk V, Langshaw EL, Calcutt A, Powell J, Batzloff MR, Rivera-Hernandez T, Good MF.

NPJ Vaccines. 2018 Apr 26;3:15. doi: 10.1038/s41541-018-0053-9. eCollection 2018.

13.

Induction of immunity following vaccination with a chemically attenuated malaria vaccine correlates with persistent antigenic stimulation.

Reiman JM, Kumar S, Rodriguez IB, Gnidehou S, Ito K, Stanisic DI, Lee M, McPhun V, Majam V, Willemsen NM, Batzloff MR, Raja AI, Dooley B, Hoffman SL, Yanow SK, Good MF.

Clin Transl Immunology. 2018 Apr 11;7(4):e1015. doi: 10.1002/cti2.1015. eCollection 2018.

14.

Gold(i) phosphine compounds as parasite attenuating agents for malaria vaccine and drug development.

Ssemaganda A, Low LM, Verhoeft KR, Wambuzi M, Kawoozo B, Nabasumba SB, Mpendo J, Bagaya BS, Kiwanuka N, Stanisic DI, Berners-Price SJ, Good MF.

Metallomics. 2018 Mar 1;10(3):444-454. doi: 10.1039/c7mt00311k. Epub 2018 Feb 21.

PMID:
29465117
15.

Interpreting challenge data from early phase malaria blood stage vaccine trials.

Good MF, Miller LH.

Expert Rev Vaccines. 2018 Mar;17(3):189-196. doi: 10.1080/14760584.2018.1435278. Epub 2018 Feb 9. Review.

PMID:
29382292
16.

Cellular interactions of covR/S mutant group A Streptococci.

Langshaw EL, Pandey M, Good MF.

Microbes Infect. 2018 Oct - Nov;20(9-10):531-535. doi: 10.1016/j.micinf.2017.12.009. Epub 2017 Dec 26. Review.

PMID:
29287985
17.

Exploiting the apicoplast: apicoplast-targeting drugs and malaria vaccine development.

Low LM, Stanisic DI, Good MF.

Microbes Infect. 2018 Oct - Nov;20(9-10):477-483. doi: 10.1016/j.micinf.2017.12.005. Epub 2017 Dec 26.

PMID:
29287981
18.

Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.

Pandey M, Powell J, Calcutt A, Zaman M, Phillips ZN, Ho MF, Batzloff MR, Good MF.

Sci Rep. 2017 Oct 23;7(1):13786. doi: 10.1038/s41598-017-14157-7.

19.

Controlled Human Malaria Infection: Applications, Advances, and Challenges.

Stanisic DI, McCarthy JS, Good MF.

Infect Immun. 2017 Dec 19;86(1). pii: e00479-17. doi: 10.1128/IAI.00479-17. Print 2018 Jan. Review.

20.

Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen.

Nordström T, Pandey M, Calcutt A, Powell J, Phillips ZN, Yeung G, Giddam AK, Shi Y, Haselhorst T, von Itzstein M, Batzloff MR, Good MF.

J Immunol. 2017 Oct 15;199(8):2794-2802. doi: 10.4049/jimmunol.1700836. Epub 2017 Sep 13.

21.

Plasmacytoid dendritic cells appear inactive during sub-microscopic Plasmodium falciparum blood-stage infection, yet retain their ability to respond to TLR stimulation.

Loughland JR, Minigo G, Sarovich DS, Field M, Tipping PE, Montes de Oca M, Piera KA, Amante FH, Barber BE, Grigg MJ, William T, Good MF, Doolan DL, Engwerda CR, Anstey NM, McCarthy JS, Woodberry T.

Sci Rep. 2017 Jun 1;7(1):2596. doi: 10.1038/s41598-017-02096-2.

22.

Chemical Attenuation in the Development of a Whole-Organism Malaria Vaccine.

Raja AI, Stanisic DI, Good MF.

Infect Immun. 2017 Jun 20;85(7). pii: e00062-17. doi: 10.1128/IAI.00062-17. Print 2017 Jul. Review.

23.

Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection: CD1c+ Myeloid Dendritic Cell Maturation Arrest, Induction of the Kynurenine Pathway, and Regulatory T Cell Activation.

Woodberry T, Loughland JR, Minigo G, Burel JG, Amante FH, Piera KA, McNeil Y, Yeo TW, Good MF, Doolan DL, Engwerda CR, McCarthy JS, Anstey NM.

Infect Immun. 2017 May 23;85(6). pii: e00986-16. doi: 10.1128/IAI.00986-16. Print 2017 Jun.

24.

Comparison of Fluorinated and Nonfluorinated Lipids in Self-Adjuvanting Delivery Systems for Peptide-Based Vaccines.

Hussein WM, Mukaida S, Azmi F, Bartlett S, Olivier C, Batzloff MR, Good MF, Skwarczynski M, Toth I.

ACS Med Chem Lett. 2017 Jan 24;8(2):227-232. doi: 10.1021/acsmedchemlett.6b00453. eCollection 2017 Feb 9.

25.

Synthesis, Characterization and Immunological Evaluation of Self-Adjuvanting Group A Streptococcal Vaccine Candidates Bearing Various Lipidic Adjuvanting Moieties.

Fagan V, Hussein WM, Su M, Giddam AK, Batzloff MR, Good MF, Toth I, Simerska P.

Chembiochem. 2017 Mar 16;18(6):545-553. doi: 10.1002/cbic.201600639. Epub 2017 Feb 15.

PMID:
28075053
26.

Streptococcal Immunity Is Constrained by Lack of Immunological Memory following a Single Episode of Pyoderma.

Pandey M, Ozberk V, Calcutt A, Langshaw E, Powell J, Rivera-Hernandez T, Ho MF, Philips Z, Batzloff MR, Good MF.

PLoS Pathog. 2016 Dec 27;12(12):e1006122. doi: 10.1371/journal.ppat.1006122. eCollection 2016 Dec.

27.

Novel platform technology for modular mucosal vaccine that protects against streptococcus.

Zaman M, Ozberk V, Langshaw EL, McPhun V, Powell JL, Phillips ZN, Ho MF, Calcutt A, Batzloff MR, Toth I, Hill GR, Pandey M, Good MF.

Sci Rep. 2016 Dec 15;6:39274. doi: 10.1038/srep39274.

28.

The Impact of Established Immunoregulatory Networks on Vaccine Efficacy and the Development of Immunity to Malaria.

Montes de Oca M, Good MF, McCarthy JS, Engwerda CR.

J Immunol. 2016 Dec 15;197(12):4518-4526. Review.

29.

Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery.

Marasini N, Giddam AK, Khalil ZG, Hussein WM, Capon RJ, Batzloff MR, Good MF, Toth I, Skwarczynski M.

Nanomedicine (Lond). 2016 Dec;11(24):3223-3235. Epub 2016 Nov 10.

PMID:
27830630
30.

Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.

Marasini N, Khalil ZG, Giddam AK, Ghaffar KA, Hussein WM, Capon RJ, Batzloff MR, Good MF, Skwarczynski M, Toth I.

Int J Pharm. 2016 Nov 20;513(1-2):410-420. doi: 10.1016/j.ijpharm.2016.09.057. Epub 2016 Sep 20.

PMID:
27659862
31.

Linear and branched polyacrylates as a delivery platform for peptide-based vaccines.

Chandrudu S, Bartlett S, Khalil ZG, Jia Z, Hussein WM, Capon RJ, Batzloff MR, Good MF, Monteiro MJ, Skwarczynski M, Toth I.

Ther Deliv. 2016 Sep;7(9):601-9. doi: 10.4155/tde-2016-0037.

PMID:
27582233
32.

A semi-synthetic whole parasite vaccine designed to protect against blood stage malaria.

Giddam AK, Reiman JM, Zaman M, Skwarczynski M, Toth I, Good MF.

Acta Biomater. 2016 Oct 15;44:295-303. doi: 10.1016/j.actbio.2016.08.020. Epub 2016 Aug 17.

PMID:
27544810
33.

Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.

Batzloff MR, Fane A, Gorton D, Pandey M, Rivera-Hernandez T, Calcutt A, Yeung G, Hartas J, Johnson L, Rush CM, McCarthy J, Ketheesan N, Good MF.

Hum Vaccin Immunother. 2016 Dec;12(12):3089-3096. doi: 10.1080/21645515.2016.1222999. Epub 2016 Aug 19.

34.

The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus.

Ghaffar KA, Marasini N, Giddam AK, Batzloff MR, Good MF, Skwarczynski M, Toth I.

Med Chem. 2016;13(1):22-27. doi: 10.2174/1573406412666160720093138.

PMID:
27449794
35.

Highly Immunogenic Trimethyl Chitosan-based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus.

Marasini N, Ghaffar KA, Giddam AK, Batzloff MR, Good MF, Skwarczynski M, Toth I.

Curr Drug Deliv. 2017;14(5):701-708. doi: 10.2174/1567201813666160721141322.

PMID:
27440071
36.

Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite.

Stanisic DI, Gerrard J, Fink J, Griffin PM, Liu XQ, Sundac L, Sekuloski S, Rodriguez IB, Pingnet J, Yang Y, Zhou Y, Trenholme KR, Wang CY, Hackett H, Chan JA, Langer C, Hanssen E, Hoffman SL, Beeson JG, McCarthy JS, Good MF.

Infect Immun. 2016 Aug 19;84(9):2689-96. doi: 10.1128/IAI.00414-16. Print 2016 Sep.

37.

Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.

Rivera-Hernandez T, Pandey M, Henningham A, Cole J, Choudhury B, Cork AJ, Gillen CM, Ghaffar KA, West NP, Silvestri G, Good MF, Moyle PM, Toth I, Nizet V, Batzloff MR, Walker MJ.

MBio. 2016 Jun 14;7(3). pii: e00618-16. doi: 10.1128/mBio.00618-16.

38.

Structure-activity relationship of lipid core peptide-based Group A Streptococcus vaccine candidates.

Chan A, Hussein WM, Ghaffar KA, Marasini N, Mostafa A, Eskandari S, Batzloff MR, Good MF, Skwarczynski M, Toth I.

Bioorg Med Chem. 2016 Jul 15;24(14):3095-101. doi: 10.1016/j.bmc.2016.03.063. Epub 2016 Apr 2.

PMID:
27246859
39.

Chemically Attenuated Blood-Stage Plasmodium yoelii Parasites Induce Long-Lived and Strain-Transcending Protection.

Raja AI, Cai Y, Reiman JM, Groves P, Chakravarty S, McPhun V, Doolan DL, Cockburn I, Hoffman SL, Stanisic DI, Good MF.

Infect Immun. 2016 Jul 21;84(8):2274-2288. doi: 10.1128/IAI.00157-16. Print 2016 Aug.

40.

Persistence and immunogenicity of chemically attenuated blood stage Plasmodium falciparum in Aotus monkeys.

De SL, Stanisic DI, van Breda K, Bellete B, Harris I, McCallum F, Edstein MD, Good MF.

Int J Parasitol. 2016 Aug;46(9):581-91. doi: 10.1016/j.ijpara.2016.05.002. Epub 2016 May 26.

PMID:
27238088
41.

Multilayer engineered nanoliposomes as a novel tool for oral delivery of lipopeptide-based vaccines against group A Streptococcus.

Marasini N, Giddam AK, Ghaffar KA, Batzloff MR, Good MF, Skwarczynski M, Toth I.

Nanomedicine (Lond). 2016 May;11(10):1223-36. doi: 10.2217/nnm.16.36. Epub 2016 Apr 14.

PMID:
27077314
42.

Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus.

Ghaffar KA, Marasini N, Giddam AK, Batzloff MR, Good MF, Skwarczynski M, Toth I.

Acta Biomater. 2016 Sep 1;41:161-8. doi: 10.1016/j.actbio.2016.04.012. Epub 2016 Apr 7.

PMID:
27063491
43.

Status of research and development of vaccines for Streptococcus pyogenes.

Steer AC, Carapetis JR, Dale JB, Fraser JD, Good MF, Guilherme L, Moreland NJ, Mulholland EK, Schodel F, Smeesters PR.

Vaccine. 2016 Jun 3;34(26):2953-2958. doi: 10.1016/j.vaccine.2016.03.073. Epub 2016 Mar 29.

44.

Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.

Pandey M, Mortensen R, Calcutt A, Powell J, Batzloff MR, Dietrich J, Good MF.

J Immunol. 2016 Apr 15;196(8):3364-74. doi: 10.4049/jimmunol.1501994. Epub 2016 Mar 11.

45.

Profoundly Reduced CD1c+ Myeloid Dendritic Cell HLA-DR and CD86 Expression and Increased Tumor Necrosis Factor Production in Experimental Human Blood-Stage Malaria Infection.

Loughland JR, Minigo G, Burel J, Tipping PE, Piera KA, Amante FH, Engwerda CR, Good MF, Doolan DL, Anstey NM, McCarthy JS, Woodberry T.

Infect Immun. 2016 Apr 22;84(5):1403-1412. doi: 10.1128/IAI.01522-15. Print 2016 May.

46.

Cryptic epitope for antibodies should not be forgotten in vaccine design.

Good MF, Yanow SK.

Expert Rev Vaccines. 2016 Jun;15(6):675-6. doi: 10.1586/14760584.2016.1154791. Epub 2016 Mar 21. No abstract available.

PMID:
26881480
47.

Current Approaches to Group A Streptococcal Vaccine Development.

Dale JB, Batzloff MR, Cleary PP, Courtney HS, Good MF, Grandi G, Halperin S, Margarit IY, McNeil S, Pandey M, Smeesters PR, Steer AC.

In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes : Basic Biology to Clinical Manifestations [Internet]. Oklahoma City (OK): University of Oklahoma Health Sciences Center; 2016-.
2016 Feb 10.

48.

Examining cellular immune responses to inform development of a blood-stage malaria vaccine.

Stanisic DI, Good MF.

Parasitology. 2016 Feb;143(2):208-23. doi: 10.1017/S0031182015001092. Epub 2016 Jan 8. Review.

PMID:
26743398
49.

Plasmodium berghei bio-burden correlates with parasite lactate dehydrogenase: application to murine Plasmodium diagnostics.

De SL, Stanisic DI, Rivera F, Batzloff MR, Engwerda C, Good MF.

Malar J. 2016 Jan 4;15:3. doi: 10.1186/s12936-015-1027-2.

50.

Evaluation of the 2-Aminomethylphenol JPC-2997 in Aotus Monkeys Infected with Plasmodium falciparum.

McCallum F, Harris I, van Breda K, De SL, Stanisic DI, Good MF, Jacobus DP, Edstein MD.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1948-9. doi: 10.1128/AAC.02799-15. No abstract available.

Supplemental Content

Support Center